Sunday 19 April 2026

One To Watch

Xaira Therapeutics

An integrated biotechnology company utilising artificial intelligence (AI) to rethink the drug discovery and development process.

Company Overview

Want to Update your Company's Profile?


Latest Xaira Therapeutics News

Can AI help biopharma identify the next blockbuster?
2 December 2024
AI drug discovery groups benefiting from venture interest as Xaira shows the way
7 August 2024
Xaira’s billion dollar raise fuels hype - and hope - for AI-led drug discovery
14 May 2024
$1 billion backing for San Fran start-up using machine learning
24 April 2024
More Xaira Therapeutics news >


Today's issue

UCB to acquire Neurona Therapeutics to advance epilepsy portfolio
Biotechnology
UCB to acquire Neurona Therapeutics to advance epilepsy portfolio
18 April 2026
Biotechnology
Athernal Bio: targeting leukemia’s precursor – before the disease takes hold
17 April 2026
Pharmaceutical
Grifols successfully completes refinancing
17 April 2026
Pharmaceutical
Kailera Therapeutics announces $625 million IPO
17 April 2026
Pharmaceutical
New leadership and financing for Achieve
17 April 2026
Biotechnology
EC approves Merck’s Enflonsia for RSV
17 April 2026
Pharmaceutical
Trump nominates Erica Schwartz as new CDC director
17 April 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze